Clinic of Hematology, University Clinical Center of Serbia, Koste Todorovica 2, 11000 Belgrade, Serbia.
Medical Faculty, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.
Medicina (Kaunas). 2024 Sep 4;60(9):1443. doi: 10.3390/medicina60091443.
: With the advent of novel therapies for nucleophosmin gene ()-mutated acute myeloid leukemia (AML), there is a growing need for the reliable prediction of mutations. This study explored the role of cytomorphological features in the early prediction of -mutated AML. : Altogether, 212 de novo AML cases with normal karyotypes, diagnosed and treated at a single institution within 5 years (2018-2023), were retrospectively evaluated. A final diagnosis of -mutated AML, based on the World Health Organization (WHO) integrated criteria, including real-time based identification of mutation and normal karyotype, was established in 83/212 (39.15%) cases. : Cup-like blasts (CLBs), a cytomorphological feature suggestive of -mutated AML, were detected in 56/83 (67%) patients. Most cases (44/56, 78.6%) had CLB ≥ 10%. In total, 27 of 83 AML -mutated patients had no CLB morphology (missed call). Additionally, two of 212 had CLB morphology without confirmed mutation (wrong call). The positive/negative predictive values of cytomorphological evaluation for CLB ≥ 10% were 95.7%/75.6%, with sensitivity/specificity of 53%/98.5%, while the accuracy was 80.7%. We noted an increased percentage of CLBs (≥15%) in 77.8% and 50% of patients with AML without and with granulocytic maturation, respectively (the specificity for mutation prediction was 100%). CLB was associated with fms-like tyrosine kinase 3 () mutation ( = 0.03), but, without statistical significance for CLB ≥ 10% and CLB ≥ 15%. : Our investigation confirmed that the morphological identification of CLB at diagnosis represents a reliable and easily reproducible tool for the early prediction of mutations, enabling a streamlined genetic work-up for its confirmation. This may facilitate considering the early administration of individualized therapies by clinicians for specific patients.
: 随着新型治疗药物的出现,核磷蛋白基因 ()-突变急性髓系白血病(AML)的治疗需求不断增长,因此对于 突变的可靠预测变得至关重要。本研究旨在探索细胞形态学特征在预测 -突变 AML 中的作用。 : 本研究回顾性分析了 2018 年至 2023 年在单家机构确诊和治疗的 212 例核型正常的初发 AML 病例。根据世界卫生组织(WHO)综合标准,包括实时识别 突变和核型正常,最终诊断为 83/212(39.15%)例 -突变 AML。 : 杯状核(CLB)是提示 -突变 AML 的细胞形态学特征,在 56/83(67%)例患者中检测到。大多数病例(44/56,78.6%)的 CLB ≥ 10%。总的来说,83 例 AML -突变患者中有 27 例(27/83,32.5%)无 CLB 形态(漏诊)。此外,212 例中有 2 例(2/212,0.9%)有 CLB 形态但未确认 突变(误诊)。细胞形态学评估对 CLB ≥ 10%的阳性/阴性预测值分别为 95.7%/75.6%,敏感性/特异性分别为 53%/98.5%,准确性为 80.7%。我们注意到,无粒细胞成熟的 AML 患者中 CLB(≥15%)的比例分别增加了 77.8%和 50%(预测 突变的特异性为 100%)。CLB 与 fms 样酪氨酸激酶 3 () 突变相关( = 0.03),但 CLB ≥ 10%和 CLB ≥ 15%的差异无统计学意义。 : 本研究证实,诊断时 CLB 的形态学识别是预测 突变的可靠且易于重复的工具,可简化其确认的遗传检测。这可能有助于临床医生为特定患者尽早实施个体化治疗。